Gilead Sciences (NASDAQ:GILD) PT Lowered to $85.00 at TD Cowen

Gilead Sciences (NASDAQ:GILD) had its target price decreased by TD Cowen from $90.00 to $85.00 in a research report released on Friday morning, Benzinga reports. TD Cowen currently has a buy rating on the biopharmaceutical company’s stock.

Several other research analysts have also issued reports on GILD. Oppenheimer reaffirmed an outperform rating and issued a $105.00 target price on shares of Gilead Sciences in a research note on Friday, April 19th. StockNews.com lowered shares of Gilead Sciences from a strong-buy rating to a buy rating in a research note on Friday, April 19th. Wells Fargo & Company reduced their target price on shares of Gilead Sciences from $84.00 to $77.00 and set an equal weight rating on the stock in a research note on Monday, March 4th. Truist Financial lowered shares of Gilead Sciences from a buy rating to a hold rating and reduced their target price for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. Finally, Royal Bank of Canada reduced their price objective on shares of Gilead Sciences from $76.00 to $74.00 and set a sector perform rating on the stock in a research note on Friday. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of Hold and a consensus price target of $83.87.

Gilead Sciences Trading Up 0.2 %

GILD opened at $65.42 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. The stock has a market capitalization of $81.45 billion, a PE ratio of 181.72, a PEG ratio of 1.17 and a beta of 0.19. Gilead Sciences has a 1-year low of $64.63 and a 1-year high of $87.86. The firm has a 50-day moving average price of $71.28 and a two-hundred day moving average price of $76.25.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, beating the consensus estimate of ($1.49) by $0.17. The firm had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 23.08%. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the company posted $1.37 EPS. As a group, equities analysts anticipate that Gilead Sciences will post 4.2 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 4.71%. The ex-dividend date is Friday, June 14th. Gilead Sciences’s payout ratio is currently 855.56%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total value of $146,360.00. Following the transaction, the insider now owns 100,936 shares of the company’s stock, valued at $7,386,496.48. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. OFI Invest Asset Management bought a new position in Gilead Sciences in the third quarter valued at approximately $26,000. Tompkins Financial Corp raised its holdings in shares of Gilead Sciences by 223.1% in the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 241 shares during the last quarter. Fortitude Family Office LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $29,000. Private Wealth Management Group LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $29,000. Finally, Sachetta LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $30,000. Institutional investors own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.